Amgen Inc. (AMGN)
| Market Cap | 154.14B |
| Revenue (ttm) | 26.83B |
| Net Income (ttm) | 7.57B |
| Shares Out | 535.18M |
| EPS (ttm) | 14.07 |
| PE Ratio | 20.47 |
| Forward PE | 14.71 |
| Dividend | $9.00 (3.13%) |
| Ex-Dividend Date | Feb 15, 2024 |
| Volume | 1,766,799 |
| Open | 287.86 |
| Previous Close | 288.46 |
| Day's Range | 286.39 - 288.49 |
| 52-Week Range | 211.71 - 289.04 |
| Beta | 0.58 |
| Analysts | Buy |
| Price Target | 283.40 (-1.6%) |
| Earnings Date | Jan 30, 2024 |
About AMGN
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment o... [Read more]
Financial Performance
In 2022, Amgen's revenue was $26.32 billion, an increase of 1.32% compared to the previous year's $25.98 billion. Earnings were $6.55 billion, an increase of 11.18%.
Financial StatementsAnalyst Forecast
According to 20 analysts, the average rating for AMGN stock is "Buy." The 12-month stock price forecast is $283.4, which is a decrease of -1.60% from the latest price.
News
Obesity drug enthusiasm can continue in 2024: Mizuho's Jared Holz
Mizuho's Jared Holz joins 'Fast Money' to talk enthusiasm surrounding obesity drugs and if that can endure into 2024.
Healthcare Stocks Had a Terrible 2023. Things Are Looking Up.
Things could hardly have gone worse for healthcare investors this year.
Amgen's NDA for Lumakras cancer treatment resulted in complete response letter
Amgen Inc. AMGN said Tuesday that the regulatory review of its supplemental new drug application seeking full approval of Lumakras resulted in a “complete response letter” from the U.S. Food and Drug ...
AMGEN PROVIDES REGULATORY UPDATE ON STATUS OF LUMAKRAS® (SOTORASIB)
FDA Has Issued New Postmarketing Requirement LUMAKRAS Dosing Confirmed at 960 mg Once-Daily for Patients With KRAS G12C-Mutated NSCLC Under Accelerated Approval THOUSAND OAKS, Calif. , Dec. 26, 2023 /...
CORE Kidney Welcomes Amgen as Lead Sponsor of the 2024 Rose Parade® Kidney Float
LOS ANGELES--(BUSINESS WIRE)-- #Amgen--CORE Kidney welcomes Amgen as lead sponsor for their 2024 Rose Parade Float along with sponsors Baxter International Inc., DaVita Inc., and Travere.
Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk?
The obesity drugs that powered huge investor gains in 2023 are poised to inspire more corporate dealmaking, scientific breakthroughs and better patient access in the year ahead, analysts say.
Amgen shares rise as analysts see ‘value obesity play'
Shares of Amgen Inc. AMGN, +0.01% gained 1.1% premarket on Tuesday after BMO Capital Markets analysts upgraded the stock to outperform, from market perform, citing the company's “underappreciated” pot...
Wells Fargo's top pharma picks for 2024
Mohit Bansal, Wells Fargo Analyst, joins 'Closing Bell: Overtime' to discuss Wells Fargo's pharma picks for 2024.
AMGEN ANNOUNCES EXECUTIVE APPOINTMENTS TO ACCELERATE INNOVATION
James Bradner, M.D., Joins as Executive Vice President, Research and Development, and Chief Scientific Officer David M.
AMGEN TO SPONSOR THE IRISH OPEN
Sponsorship of the Golf Event Continues Following Horizon Acquisition Golfers Shane Lowry, Pádraig Harrington, Séamus Power and Brendan Lawlor Will Become Amgen Golf Ambassadors THOUSAND OAKS, Calif. ...
FDA Grants Priority Review to Amgen's Tarlatamab Application for Advanced Small Cell Lung Cancer
Currently There are no Approved Therapeutic Options for Third-Line Treatment of Advanced SCLC1 If Approved, Tarlatamab Would be the First BiTE® Therapy for a Major Solid Tumor FDA Target Action Date i...
Amgen raises dividend to $2.25 a share
Amgen Inc. AMGN, +0.68% said late Tuesday its board has authorized a dividend of $2.25 a share, up from $2.13 a share. That's the 12th straight year that Amgen has increased its dividend, the company ...
AMGEN ANNOUNCES 2024 FIRST QUARTER DIVIDEND INCREASE TO $2.25 PER SHARE
THOUSAND OAKS, Calif. , Dec. 12, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.25 per share dividend for the first quarter of 2024.
3 Dividend Stocks for December 2023
#Morningstar #Fidelity #DividendStocks The dividend prospects for three firms with economic moats. 00:00 Introduction 00:10 Amgen AMGN 00:56 Enbridge ENB 01:56 Fidelity National Information Services ...
AMGEN HIGHLIGHTS HEMATOLOGY PORTFOLIO AT ASH 2023
Multiple Investigator Sponsored Studies Support the Potential of BLINCYTO® (blinatumomab) Across Acute Lymphoblastic Leukemia Treatment Paradigm New Data Reinforce KYPROLIS® (carfilzomib) as an Impor...
AMGEN TO PRESENT AT THE EVERCORE ISI HEALTHCONX CONFERENCE
THOUSAND OAKS, Calif. , Nov. 22, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Evercore ISI HealthCONx Conference at 9:10 a.m.
New ETF invested in Ozempic maker and exposed to other obesity drugs falls in first day of trade
A new ETF hit the market Tuesday, creating buzz for its exposure to popular weight-loss drugs, while expanding the roster of thematic ETFs available for investors willing to pay up for stock-picking p...
6 intriguing stocks investors should consider: Piper Sandler
The market has slightly rebounded, with some investors excited for a possible Santa Claus rally to close out the year. Piper Sandler's technical research team announced six stocks that are currently l...
AMGEN PRESENTS NEW CARDIOVASCULAR RESEARCH AT AHA 2023
New Repatha® (evolocumab) Data Show No Decline in Cognitive Function Associated With Very Low Levels of LDL-C Olpasiran Research Provides Further Insights Into Cardiovascular Risks Associated With Ele...
US Senator Elizabeth Warren expresses 'disappointment' in FTC's Amgen decision
Senator Elizabeth Warren, an antitrust hawk, expressed disappointment with the U.S. Federal Trade Commission's decision to allow pharmaceutical firm Amgen to move forward with its acquisition of Horiz...
AMGEN PRESENTS NEW RESEARCH IN EARLY PSORIATIC ARTHRITIS AT ACR 2023
FOREMOST Study Finds Oral Otezla ® (apremilast) Significantly Improved Disease Control vs. Placebo THOUSAND OAKS, Calif.